{
    "nct_id": "NCT03102320",
    "official_title": "Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies",
    "inclusion_criteria": "* Availability of tumor tissue for mesothelin expression testing and for further biomarker analysis\n* Histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria)\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (or for thymic carcinoma, at least one measurable lesion per International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 criteria\n* Adequate bone marrow, liver, renal and coagulation function\n* Left ventricular ejection fraction (LVEF) â‰¥ 50% of the lower limit of normal (LLN) according to local institutional ranges\n* Eastern Cooperative Oncology Group (ECOG) 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Exposure to more than one prior anti-tubulin/microtubule agent\n* Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition\n* Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Contraindication to both CT and MRI contrast agents\n* Active hepatitis B or C infection\n* Pregnant or breast-feeding patients\n* Tumor type specific exclusion criteria",
    "miscellaneous_criteria": ""
}